In charge of budgeting, forecasting, financial reporting, and strategic planning for 5 Global Client Business Lines with matrix structure, covering diverse investments in Fixed Income, Alternatives, Equity products, Mutual Funds, and Mega Mandates. Provide strategic direction, ongoing reporting, and analysis for business operations, supporting Business Heads, Senior Leadership, and Investor Relation with ad hoc analysis. Instrumental in spearheading reporting transformation and digitalization efforts resulting in increased reporting efficiency.

Executed financial reporting within the Wealth Management Private Banking, achieving a successful revamp of financial reporting resulting in significant increase in insights into business performance by introducing key performance indicators (KPIs) and implementing comprehensive budgeting, forecasting, and periodic reporting for new product launches. Developed financial models for revenue structure, variance and trend analysis as well as supported treasury with capital allocation analysis, enabling them to effectively perform asset reserves and trading activities.

Performed central consolidation function for expenses and P&Ls for 6 Pharma franchises. Drove cross-functional central reporting process and filings supporting CFO office and challenging franchises forecasts to ensure optimal use of funds. Supported senior leadership with ad hoc requests, delivering financial insights and analysis for leadership meetings.

Consolidated financial reporting for 6 Business Units on a corporate level, performing month-end closing, forecasting, budgeting, strategic plan processes, and variance analysis, enhancing month end close process.

Held full responsibility for building the financial, accounting and business infrastructure of a pharmaceutical start-up, ensuring the accuracy and integrity of all financial data.

Handled performance data analysis, profitability evaluation, sales and variance analyses. Performed What-If, scenario, sensitivity, and risk analyses. Charged with accountability for evaluating global new investment projects within a $140M global pharmaceutical company. Executed financial reporting consolidation and analysis across 8 global offices. Performed financial modeling to assess and make recommendations for new product development and marketing investments.